ALFASIGMA At CDMO Live in Rotterdam, 24/7 BIOPHARMA took the opportunity to meet Morpho, the Contract Development and Manufacturing Organisation (CDMO) of Alfasigma, which recently unveiled its new brand identity. This rebranding marked a significant milestone in Morpho’s journey, reflecting a renewed strategic focus and forward-looking vision, but what defines Morpho today? What trajectory is it pursuing? Most importantly, what are the key pillars supporting its growth and shaping its future? Heritage and vision Morpho, Alfasigma’s CDMO Business Unit, is built on more than 75 years of pharmaceutical excellence and continuous evolution. Over time, Alfasigma’s Contract Manufacturing Organisation (CMO) expanded its capabilities, evolving into a dynamic, full-service CDMO, one that combines a strong legacy with a clear ambition for the future. This transformation reflects an increasing emphasis on development activities in addition to manufacturing. Morpho’s capabilities span a wide range of pharmaceutical dosage forms, including sterile injectables, vaccines, oral solids, semi-solids, and more. These products are supported by advanced formulation research, clinical batch preparation and process validation services. It offers end-toend pharmaceutical and nutraceutical solutions, tailored to meet the specific needs of partners worldwide. Strategic direction During CDMO Live, Rocco Paracchini, MorphoCDMO Director at Alfasigma, highlighted the central role of partnership excellence. He explained: “Strong partnerships are not transactional. They are built on mutual goals, shared values and the willingness to grow together”. He noted that successful partnerships are built on strong commitment, with transactional collaborations serving short-term needs and strategic alliances requiring long-term alignment. He identified six key pillars of effective collaboration: mutual benefit, trust, duration, transparent communication, reliability and growth potential. These principles form the foundation for lasting partnerships that drive innovation and shared success. 46 TWENTYFOURSEVENBIOPHARMA Issue 2 / June 2025
RkJQdWJsaXNoZXIy MjY2OTA4MA==